Rare & Genetic · Clinical trials
Angelman Syndrome Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About angelman syndrome — and why its trials are hard
Angelman syndrome is a rare neurodevelopmental disorder caused by loss of function of the maternally inherited UBE3A gene on chromosome 15q11-q13, most often via deletion, uniparental disomy, imprinting defects, or UBE3A mutation. Because the paternal UBE3A copy is silenced in neurons, affected individuals have essentially no neuronal UBE3A expression, producing severe developmental delay, near-absent speech, ataxia and movement/balance problems, epilepsy, sleep disturbance, and a characteristic happy demeanor. There is NO FDA-approved disease-modifying therapy; management is entirely symptomatic (anti-seizure medications, sleep and behavioral support, physical/occupational/speech therapy), representing a high unmet need. The most advanced disease-modifying strategy is antisense oligonucleotides (ASOs) designed to 'unsilence' the paternal UBE3A allele by degrading the UBE3A-antisense transcript. Several ASO programs are in clinical development, including GTX-102 (apazunersen, Ultragenyx; Phase 3 Aspire), rugonersen (Roche), and ION582 (Ionis). The field has faced setbacks: early ASO dosing encountered safety signals (e.g., transient lower-extremity weakness prompting a clinical hold) and other programs have been paused, illustrating both the promise and the challenges of genetic therapy for Angelman syndrome.
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in angelman syndrome development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| GTX-102 (apazunersen) — Phase 1/2 (Ultragenyx; earlier development) | Development interrupted by a clinical hold after higher-dose cohorts experienced transient lower-extremity weakness; program later resumed with revised dosing and advanced to Phase 3 (Aspire) | Intrathecal ASO dose/localized inflammatory effects created a dose-limiting safety signal early, requiring protocol/dose modification (unverified exact details) |
| rugonersen / other ASO programs — Early-phase ASO studies (various sponsors) | Multiple UBE3A-unsilencing programs have been paused or slowed during development; no candidate has yet demonstrated a pivotal positive outcome (unverified) | Challenges include intrathecal delivery, dosing/safety optimization, and defining validated efficacy endpoints in a heterogeneous pediatric population |
Choosing the right endpoint
Primary endpoints that matter in angelman syndrome trials
- UBE3A expression / target engagement — Biomarker demonstrating that an ASO successfully unsilences the paternal UBE3A allele in neurons
- Developmental/cognitive scales (e.g., Bayley, Vineland) — Assess global development, communication, and adaptive behavior in this severely impaired population
- Communication and expressive language measures — Near-absent speech is a defining feature; gains here are highly meaningful to families
- Seizure frequency and sleep outcomes — Common, burdensome comorbidities used as functional/quality-of-life endpoints
How iNGENū runs angelman syndrome trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Angelman Syndrome clinical trials — FAQs
Is there an approved treatment for Angelman syndrome?
What is the leading experimental approach?
Why has drug development been difficult?
Ready to discuss your angelman syndrome trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal